1800-272-662
Shopping Cart 0
countryflagAU
Login

Smith & Nephew SNATS Inc

Healthcare US SNN

33.06USD
-1.02(2.99%)

Last update at 2026-03-10T20:01:00Z

Day Range

32.9734.06
LowHigh

52 Week Range

21.5332.68
LowHigh

Fundamentals

  • Previous Close 34.08
  • Market Cap11952.45M
  • Volume1443064
  • P/E Ratio54.74
  • Dividend Yield2.75%
  • EBITDA1135.00M
  • Revenue TTM5349.00M
  • Revenue Per Share TTM2.46
  • Gross Profit TTM 3695.00M
  • Diluted EPS TTM0.50

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 235.00M 586.00M 246.00M 743.00M 781.00M
Minority interest - - - - -
Net income 223.00M 524.00M 448.00M 600.00M 663.00M
Selling general administrative 2880.00M 2720.00M 2562.00M 2693.00M 2497.00M
Selling and marketing expenses 2066.00M 2013.00M 1773.00M 1911.00M 1820.00M
Gross profit 3675.00M 3669.00M 3164.00M 3800.00M 3606.00M
Reconciled depreciation 628.00M 581.00M 562.00M 502.00M 435.00M
Ebit 315.00M 591.00M 308.00M 808.00M 840.00M
Ebitda 943.00M 1172.00M 904.00M 1326.00M 1294.00M
Depreciation and amortization 628.00M 581.00M 596.00M 518.00M 454.00M
Non operating income net other - - - - -
Operating income 450.00M 593.00M 295.00M 815.00M 863.00M
Other operating expenses 4765.00M 4619.00M 4265.00M 4323.00M 4041.00M
Interest expense 80.00M 80.00M 62.00M 65.00M 59.00M
Tax provision 12.00M 62.00M -202.00000M 143.00M 118.00M
Interest income 14.00M 6.00M 6.00M 43.00M 52.00M
Net interest income -74.00000M -91.00000M -63.00000M -73.00000M -71.00000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 12.00M 62.00M -202.00000M 143.00M 118.00M
Total revenue 5215.00M 5212.00M 4560.00M 5138.00M 4904.00M
Total operating expenses 3225.00M 3076.00M 2869.00M 2985.00M 2743.00M
Cost of revenue 1540.00M 1543.00M 1396.00M 1338.00M 1298.00M
Total other income expense net -430.00000M -126.00000M -187.00000M -238.00000M -195.00000M
Discontinued operations - - - - -
Net income from continuing ops 223.00M 524.00M 448.00M 600.00M 663.00M
Net income applicable to common shares 223.00M 524.00M 448.00M 600.00M 663.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 9966.00M 10920.00M 11012.00M 9299.00M 8059.00M
Intangible assets 1236.00M 1398.00M 1486.00M 1567.00M 1210.00M
Earning assets - - - - -
Other current assets 9027.00M 1290.00M 1211.00M 1328.00M 1317.00M
Total liab 4707.00M 5352.00M 5733.00M 4158.00M 3185.00M
Total stockholder equity 5259.00M 5568.00M 5279.00M 5141.00M 4874.00M
Deferred long term liab - - - - -
Other current liab 686.00M 1088.00M 797.00M 623.00M 611.00M
Common stock 175.00M 177.00M 177.00M 177.00M 177.00M
Capital stock 175.00M 177.00M 177.00M 177.00M 177.00M
Retained earnings 5026.00M 5225.00M 4958.00M 4849.00M 4625.00M
Other liab 280.00M 373.00M 692.00M 619.00M 419.00M
Good will 3031.00M 2989.00M 2928.00M 2789.00M 2337.00M
Other assets 330.00M 398.00M 368.00M 291.00M 234.00M
Cash 350.00M 1290.00M 1762.00M 277.00M 365.00M
Cash and equivalents - - - - -
Total current liabilities 1715.00M 2131.00M 1688.00M 1564.00M 1465.00M
Current deferred revenue -229.00000M -544.00000M -468.00000M -177.00000M -267.00000M
Net debt 2522.00M 2049.00M 1928.00M 1770.00M 1100.00M
Short term debt 160.00M 491.00M 337.00M 72.00M 164.00M
Short long term debt 111.00M 435.00M 279.00M 26.00M 164.00M
Short long term debt total 2872.00M 3339.00M 3690.00M 2047.00M 1465.00M
Other stockholder equity -5201.00000M -5402.00000M -5135.00000M -5026.00000M -4802.00000M
Property plant equipment 1455.00M 1513.00M 1449.00M 1323.00M 1062.00M
Total current assets 3856.00M 4424.00M 4664.00M 3219.00M 3077.00M
Long term investments - - - 110.00M 139.00M
Net tangible assets 992.00M 1181.00M 865.00M 785.00M 1327.00M
Short term investments - -182.00000M -133.00000M -106.00000M -
Net receivables -7726.00000M 1290.00M 1106.00M 1227.00M 1211.00M
Long term debt 2565.00M 2707.00M 3207.00M 1835.00M 1301.00M
Inventory 2205.00M 1844.00M 1691.00M 1614.00M 1395.00M
Accounts payable 1098.00M 1096.00M 1022.00M 1046.00M 957.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -311.00000M -2034.00000M -1821.00000M
Additional paid in capital - - - - -
Common stock total equity - - 177.00M 177.00M 177.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - -120.00000M -157.00000M -189.00000M -214.00000M
Accumulated amortization - - - - -
Non currrent assets other 153.00M 197.00M 166.00M 141.00M 108.00M
Deferred long term asset charges - - - - -
Non current assets total 6110.00M 6496.00M 6348.00M 6080.00M 4982.00M
Capital lease obligations 196.00M 197.00M 204.00M 170.00M -
Long term debt total 2712.00M 2848.00M 3353.00M 1975.00M 1301.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -472.00000M 2.00M -606.00000M -1251.00000M -378.00000M
Change to liabilities -25.00000M 82.00M -103.00000M 201.00M 71.00M
Total cashflows from investing activities -472.00000M -691.00000M -606.00000M -1251.00000M -378.00000M
Net borrowings -450.00000M -326.00000M 1490.00M 379.00M -7.00000M
Total cash from financing activities -926.00000M -645.00000M 1164.00M 7.00M -371.00000M
Change to operating activities - -150.00000M 1.00M -4.00000M -35.00000M
Net income 235.00M 586.00M 246.00M 743.00M 781.00M
Change in cash -941.00000M -466.00000M 1494.00M -76.00000M 178.00M
Begin period cash flow 1285.00M 1751.00M 257.00M 333.00M 155.00M
End period cash flow 344.00M 1285.00M 1751.00M 257.00M 333.00M
Total cash from operating activities 468.00M 877.00M 935.00M 1168.00M 931.00M
Issuance of capital stock 6.00M 14.00M 11.00M 11.00M 13.00M
Depreciation 628.00M 581.00M 596.00M 518.00M 454.00M
Other cashflows from investing activities -114.00000M -283.00000M -163.00000M -843.00000M -31.00000M
Dividends paid -327.00000M -329.00000M -328.00000M -318.00000M 321.00M
Change to inventory -407.00000M -151.00000M -45.00000M -204.00000M -152.00000M
Change to account receivables -103.00000M -81.00000M 209.00M 30.00M -108.00000M
Sale purchase of stock -158.00000M -59.00000M -16.00000M -63.00000M -48.00000M
Other cashflows from financing activities 434.00M -4.00000M 1902.00M 1242.00M -8.00000M
Change to netincome 232.00M -78.00000M -120.00000M 49.00M 65.00M
Capital expenditures 358.00M 408.00M 443.00M 408.00M 347.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -535.00000M -150.00000M 61.00M 27.00M -189.00000M
Stock based compensation 40.00M 41.00M 26.00M 32.00M 35.00M
Other non cash items 66.00M 74.00M 56.00M 55.00M -375.00000M
Free cash flow 110.00M 469.00M 492.00M 760.00M 584.00M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SNN
Smith & Nephew SNATS Inc		 -1.02 2.99% 33.06 54.74 13.99 2.20 2.22 2.82 16.82
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew SNATS Inc

Building 5, Watford, United Kingdom, WD18 8YE

Key Executives

Name Title Year Born
Ms. Anne-Francoise Nesmes CFO & Exec. Director 1972
Dr. Deepak S. Nath Ph.D. CEO & Director 1973
Mr. Paul Connolly Pres of Global Operations 1968
Mr. Andrew Swift VP of Investor Relations NA
Ms. Helen Barraclough Group Gen. Counsel, Company Sec. & Director 1979
Ms. Alison Parkes Chief Compliance Officer 1972
Mr. Joe Metzger Sr. VP of Marketing Services & Communications NA
Ms. Elga Lohler Chief HR Officer 1968
Mr. Philip G. Cowdy Chief Bus. Devel. & Corp. Affairs Officer 1967
Mr. Bradley Cannon Pres of Orthopaedics, Sports Medicine & ENT and Americas 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.